LCLAT1 and metabolic dysfunction-associated steatotic liver disease: The targeted inactivation of ALCAT1 prevents conditions like diet-induced obesity, non-alcoholic fatty liver disease (NAFLD), and MPTP-induced neurotoxicity, can ameliorate deficiency, and inhibits apoptosis [31,33,34].